Physician profile
Eugene Miknowski
NPI 1457329567
$4,935.23
in general payments reported to CMS, 2019-2025
32 companies · $850 in 2025
The $850 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $148 · 2021: $228 · 2022: $719 · 2023: $1,282 · 2024: $979 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.35 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $968.42 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $929.06 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $456.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $398.38 | 2019-2025 | Benlysta, Shingrix, Arexvy |
| Novo Nordisk INC | $329.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $269.35 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $226.97 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $190.13 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Aurinia Pharma U.S., INC. | $160.75 | 2023-2024 | Lupkynis |
| Exact Sciences Corporation | $146.99 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $145.59 | 2019-2023 | |
| Pfizer INC. | $136.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $76.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $66.35 | 2019-2025 | Airsupra |
| Allergan, INC. | $53.76 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $38.85 | 2025 | Acthar |
| Phadia US INC. | $38.13 | 2019-2024 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $35.74 | 2022 | |
| Astellas Pharma US INC | $34.01 | 2024 | Veozah |
| Gilead Sciences, INC. | $30.49 | 2021 | |
| Hikma Pharmaceuticals USA | $24.34 | 2019 | |
| Celgene Corporation | $23.97 | 2019 | |
| Horizon Therapeutics Plc | $20.91 | 2020 | |
| Hologic Sales and Service, LLC | $18.79 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.36 | 2021 | |
| Genentech USA, INC. | $16.70 | 2021 | |
| Sanofi Pasteur INC. | $16.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2025 | Zoryve |
| Medtronic, INC. | $13.10 | 2024 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $12.68 | 2019 | |
| Sebela Pharmaceuticals INC. | $12.27 | 2019 | |
| Aytu Biopharma, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Miknowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.